State Legislative Landscape in 2025 Despite a significant number of bills in 2023 and 2024 that would have required mandated coverage of GLP-1s in Medicaid, state employee health plans, or for health insurers regulated by the state, only Arkansas, California, Maryland, New Mexico, Pennsylvania, and Texas have introduced legislation mandating coverage in 2025 to date
More chronic, placebo-controlled human studies are required to evaluate not only the bioavailability and efficacy of various polyphenol formulations and delivery systems but also to establish standardized dosages, monitor potential side effects, and assess inter-individual differences in responses due to genetics and gut microbiota composition (126, 127)
Simultaneously, strategic CDMO moves are underway: Novo Holdings $16.5 billion acquisition of Catalent (plus an $11 billion transfer of three Catalent plants) was explicitly aimed at ramping Wegovy/Ozempic output ( [10] ) ( [11] )
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Brightens skin tone, & fades dark spots
